## STIC Biotechnology Systems Branch

## RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	10/551.004
Source:	Pur
Date Processed by STIC:	10/7/05

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 4.2.2 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- 3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
  U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05



PCT

RAW SEQUENCE LISTING DATE: 10/07/2005 PATENT APPLICATION: US/10/551,004 TIME: 10:13:40 Input Set: A:\31098pw1.app Output Set: N:\CRF4\10072005\J551004.raw 3 <110> APPLICANT: APOGENIX Biotechnology AG 5 <120> TITLE OF INVENTION: Imployed 7 <130> FILE REFERENCE: 31098PWO-HC

C--> 9 <140> CURRENT APPLICATION NUMBER: US/10/551,004

10 <141> CURRENT FILING DATE: 2005-09-26 Ff Pul E Po 4/03239

\*\*OTTECTION 14/003239

\*\*OTTECTION 14/003239 15 <160> NUMBER OF SEQ ID NOS: 82 17 <170> SOFTWARE: PatentIn Ver. 2.1 see R6, too 19 <210> SEQ ID NO: 1 20 <211> LENGTH: 30 21 <212> TYPE: DNA 22 <213> ORGANISM: Artificial Sequence 24 <220> FEATURE: 25 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer for the amplification of CD95 cDNA 26 28 <220> FEATURE: 29 <223> OTHER INFORMATION: Sense huCD95-Hind III 31 <400> SEQUENCE: 1 32 tataaagctt gccaccatgc tgggcatctg 30 35 <210> SEQ ID NO: 2

41 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer for

42

36 <211> LENGTH: 27

37 <212> TYPE: DNA

44 <220> FEATURE:

the amplification of CD95 cDNA

38 <213> ORGANISM: Artificial Sequence

40 <220> FEATURE:

45 <223> OTHER INFORMATION: Antisense huCD95-BgI II

47 <400> SEQUENCE: 2

48 tataagatct ggatccttcc tctttgc 27

51 <210> SEQ ID NO: 3

52 <211> LENGTH: 30

53 <212> TYPE: DNA

54 <213> ORGANISM: Artificial Sequence

56 <220> FEATURE:

57 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer

for the amplification of IgG1 Fc cDNA 58

60 <220> FEATURE:

61 <223> OTHER INFORMATION: Sense hulgG1Fc-BgIII

63 <400> SEQUENCE: 3

64 tataagatct tgtgacaaaa ctcacacatg

67 <210> SEQ ID NO: 4

30

Input Set : A:\31098pw1.app

Output Set: N:\CRF4\10072005\J551004.raw

68 <211> LENGTH: 30 69 <212> TYPE: DNA 70 <213> ORGANISM: Artificial Sequence 72 <220> FEATURE: 73 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer for the amplification of IgG1 Fc cDNA 74 76 <220> FEATURE: 77 <223> OTHER INFORMATION: Antisense hulgG1Fc-XhoI 79 <400> SEQUENCE: 4 80 tatactcgag tcatttaccc ggagacaggg 30 83 <210> SEQ ID NO: 5 84 <211> LENGTH: 31 85 <212> TYPE: DNA 86 <213> ORGANISM: Artificial Sequence 88 <220> FEATURE: 89 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer for the changing the Kozak Sequence from GCCACCATGC to 90 GCCGCCACCATGG 91 93 <220> FEATURE: 94 <223> OTHER INFORMATION: ShuCD95EC\_altKozak 96 <400> SEQUENCE: 5 97 tataaagctt gccgccacca tggtgggcat c 31 100 <210> SEQ ID NO: 6 101 <211> LENGTH: 30 102 <212> TYPE: DNA 103 <213> ORGANISM: Artificial Sequence 105 <220> FEATURE: 106 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer for the changing the Kozak Sequence from 107 108 GCCACCATGC to GCCGCCACCATGG 110 <220> FEATURE: 111 <223> OTHER INFORMATION: AS698 hulgG1Fc-Xho1 113 <400> SEQUENCE: 6 114 tatactcgag tcatttaccc ggagacaggg 30 117 <210> SEQ ID NO: 7 118 <211> LENGTH: 38 119 <212> TYPE: DNA 120 <213> ORGANISM: Artificial Sequence 122 <220> FEATURE: 123 <223> OTHER INFORMATION: Description of Artificial Sequence: primer for amplifying cDNA of human IgG1 Fc (partial hinge 124 125 CH3) 127 <220> FEATURE: 128 <223> OTHER INFORMATION: Sense hulgG1 130 <400> SEQUENCE: 7 131 ccagggactc ctgcctcttg tgacaaaact cacacatg 38 134 <210> SEQ ID NO: 8

135 <211> LENGTH: 30

136 <212> TYPE: DNA

Input Set: A:\31098pw1.app

Output Set: N:\CRF4\10072005\J551004.raw

137 <213> ORGANISM: Artificial Sequence 139 <220> FEATURE: 140 <223> OTHER INFORMATION: Description of Artificial Sequence: primer for amplifying cDNA of human IgG1 Fc (partial hinge 141 CH3) 142 144 <220> FEATURE: 145 <223> OTHER INFORMATION: Antisense ERIhulgG1 147 <400> SEQUENCE: 8 148 tatagaattc tcatttaccc ggagacaggg 30 151 <210> SEQ ID NO: 9 152 <211> LENGTH: 40 153 <212> TYPE: DNA 154 <213> ORGANISM: Artificial Sequence 156 <220> FEATURE: 157 <223> OTHER INFORMATION: Description of Artificial Sequence: primer used to amplify the cDNA of TRAILR2 domain 158 160 <220> FEATURE: 161 <223> OTHER INFORMATION: Sense HIII TRAILR2 163 <400> SEQUENCE: 9 164 tataaagctt gccgccacca tggaacaacg gggacagaac 40 167 <210> SEQ ID NO: 10 168 <211> LENGTH: 33 169 <212> TYPE: DNA 170 <213> ORGANISM: Artificial Sequence 172 <220> FEATURE: 173 <223> OTHER INFORMATION: Description of Artificial Sequence: primer used to amplify the cDNA of TRAILR2 domain 174 176 <220> FEATURE: 177 <223> OTHER INFORMATION: Antisense TRAILR2 179 <400> SEQUENCE: 10 180 gtgagttttg tcacaagagg caggagtccc tgg 33 183 <210> SEQ ID NO: 11 184 <211> LENGTH: 40 185 <212> TYPE: DNA 186 <213> ORGANISM: Artificial Sequence 188 <220> FEATURE: 189 <223> OTHER INFORMATION: Description of Artificial Sequence: primer for PCR used to utlilize fragments for cloning purposes 190 192 <220> FEATURE: 193 <223> OTHER INFORMATION: Sense\_HIII\_TRAILR2 195 <400> SEQUENCE: 11 196 tataaagctt gccgccacca tggaacaacg gggacagaac 40 199 <210> SEQ ID NO: 12 200 <211> LENGTH: 30 201 <212> TYPE: DNA 202 <213> ORGANISM: Artificial Sequence 204 <220> FEATURE: 205 <223> OTHER INFORMATION: Description of Artificial Sequence: primer for

PCR used to utlilize fragments for cloning

206

Input Set: A:\31098pw1.app

Output Set: N:\CRF4\10072005\J551004.raw

```
207
          purposes
209 <220> FEATURE:
210 <223> OTHER INFORMATION: Antisense ERIhulgG1
212 <400> SEQUENCE: 12
                                                                        30
213 tatagaattc tcatttaccc ggagacaggg
216 <210> SEQ ID NO: 13
217 <211> LENGTH: 335
218 <212> TYPE: PRT
219 <213> ORGANISM: human
221 <220> FEATURE:
222 <223> OTHER INFORMATION: CD95 >sp/P25445/TNR6 HUMAN Tumor necrosis factor
          receptor superfamily 6 precursor (FASL-receptor)
223
          (Apoptosis-mediating surface antigen FAS) (Apo-1
224
          antigen) (CD95) - Homo sapiens (Human)
225
227 <400> SEQUENCE: 13
228 Met Leu Gly Ile Trp Thr Leu Leu Pro Leu Val Leu Thr Ser Val Ala
229
                                                               15
                                          10
231 Arg Leu Ser Ser Lys Ser Val Asn Ala Gln Val Thr Asp Ile Asn Ser
232
                 20
                                      25
                                                          30
234 Lys Gly Leu Glu Leu Arg Lys Thr Val Thr Thr Val Glu Thr Gln Asn
235
             35
                                  40
                                                      45
237 Leu Glu Gly Leu His His Asp Gly Gln Phe Cys His Lys Pro Cys Pro
238
         50
                             55
                                                  60
240 Pro Gly Glu Arg Lys Ala Arg Asp Cys Thr Val Asn Gly Asp Glu Pro
241 65
                         70
                                              75
                                                                   80
243 Asp Cys Val Pro Cys Gln Glu Gly Lys Glu Tyr Thr Asp Lys Ala His
244
                     85
                                          90
                                                               95
246 Phe Ser Ser Lys Cys Arg Arg Cys Arg Leu Cys Asp Glu Gly His Gly
247
                100
                                     105
249 Leu Glu Val Glu Ile Asn Cys Thr Arg Thr Gln Asn Thr Lys Cys Arg
250
            115
                              120
                                                     125
252 Cys Lys Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu His Cys Asp
253
        130
                            135
                                                 140
255 Pro Cys Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys Thr Leu Thr
                                                                  160
256 145
                        150
                                             155
258 Ser Asn Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Asn Leu Gly Trp
259
                    165
                                         170
261 Leu Cys Leu Leu Leu Pro Ile Pro Leu Ile Val Trp Val Lys Arg
262
                180
                                     185
264 Lys Glu Val Gln Lys Thr Cys Arg Lys His Arg Lys Glu Asn Gln Gly
265
            195
                                 200
                                                     205
267 Ser His Glu Ser Pro Thr Leu Asn Pro Glu Thr Val Ala Ile Asn Leu
268
        210
                            215
                                                 220
270 Ser Asp Val Asp Leu Ser Lys Tyr Ile Thr Thr Ile Ala Gly Val Met
271 225
                        230
                                             235
                                                                  240
273 Thr Leu Ser Gln Val Lys Gly Phe Val Arg Lys Asn Gly Val Asn Glu
274
                    245
                                         250
                                                             255
276 Ala Lys Ile Asp Glu Ile Lys Asn Asp Asn Val Gln Asp Thr Ala Glu
277
                                     265
                                                         270
                260
```

Input Set : A:\31098pw1.app

Output Set: N:\CRF4\10072005\J551004.raw

```
279 Gln Lys Val Gln Leu Leu Arg Asn Trp His Gln Leu His Gly Lys Lys
280
            275
                                 280
                                                      285
282 Glu Ala Tyr Asp Thr Leu Ile Lys Asp Leu Lys Lys Ala Asn Leu Cys
283
        290
                             295
                                                  300
285 Thr Leu Ala Glu Lys Ile Gln Thr Ile Ile Leu Lys Asp Ile Thr Ser
286 305
                        310
                                                                  320
                                             315
288 Asp Ser Glu Asn Ser Asn Phe Arg Asn Glu Ile Gln Ser Leu Val
289
                    325
                                         330
                                                              335
293 <210> SEQ ID NO: 14
294 <211> LENGTH: 330
295 <212> TYPE: PRT
296 <213> ORGANISM: human
298 <220> FEATURE:
299 <223> OTHER INFORMATION: IgG1 > sp/P01857/GC1_HUMAN Ig gamma-1 chain C
300
          region - Homo sapiens (Human)
302 <400> SEQUENCE: 14
303 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
304
                                                               15
                                          10
306 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
307
                 20
                                                           30
309 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
             35
310
                                                       45
312 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
313
                              55
                                                   60
         50
315 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
316 65
                         70
                                              75
                                                                   80
318 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
319
                     85
                                          90
                                                               95
321 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
322
                100
                                     105
                                                          110
324 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
325
            115
                                 120
                                                      125
327 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
328
        130
                             135
                                                  140
330 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
331 145
                        150
                                             155
                                                                  160
333 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
334
                    165
                                         170
336 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
337
                                                          190
                180
                                     185
339 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
340
            195
                                 200
                                                      205
342 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
343
        210
                             215
                                                  220
345 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
346 225
                        230
                                             235
                                                                  240
348 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
349
                    245
                                         250
                                                              255
351 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
```

<210> 19

<211> 468

<212> PRT

<213> human

<220>

<223> TRAIL-R1 >sp/000220/T10A\_HUMAN Tumor necrosis
 factor receptor superfamily member 10A precursor
 (Death receptor 4) (TNF-related

2207 (apoptosis-including ligand receptor 1) (TRAIL (2737 receptor-1) (TRAIL-R1)

<400> 19

IMPORTANT

The types of errors shown exist throughout the Sequence Listing. Please check subsequent sequences for similar curors.

Per 1.823 A Seguence Rulie, a mAX/mum D 4 levis for 22237 resporse.

Please ersert a 22207 above fifth

luie and a C2237

at beginning of fifth

live

The above is a sample of a global ein.

## VERIFICATION SUMMARY PATENT APPLICATION: US/10/551,004 DATE: 10/07/2005 TIME: 10:13:41

Input Set : A:\31098pw1.app

Output Set: N:\CRF4\10072005\J551004.raw

```
L:9 M:270 C: Current Application Number differs, Replaced Current Application Number
L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:540 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:781 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:901 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:908 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:938 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:968 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:998 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1028 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1058 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1106 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1133 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1160 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1187 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1211 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1461 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1551 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1581 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1611 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1641 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1671 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1698 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1746 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1776 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1806 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1836 M:259 W: Allowed number of lines exceeded, <223> Other Information:
L:1866 M:259 W: Allowed number of lines exceeded, <223> Other Information:
```